Related Experiment Video
Updated: Feb 23, 2026
Author Spotlight: Exploring the Relationship Between Lipotoxicity and HFpEF
Published on: March 29, 2024
MDG-1, a Potential Regulator of PPARα and PPARγ, Ameliorates Dyslipidemia in Mice
Xu Wang1, Linlin Shi2, Sun Joyce3
1Engineering Research Center of Modern Preparation Technology of TCM, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China. xuwang0415@126.com.
Abstract:
Hyperlipidemia is a serious epidemic disease caused by lipid metabolism disorder, which is harmful to human health. MDG-1, a β-d-fructan polysaccharide extracted from Ophiopogon japonicus, has been shown to improve abnormal blood lipid levels and alleviate diabetes. However, the underlying mechanism on hyperlipidemia is largely unknown. In this study, male C57BL/6 mice were randomly separated into three groups, respectively: low-fat diet (Con), high-fat diet (HFD), and high-fat diet plus 5‰ MDG-1 (HFD + MDG-1). Body weight was measured and the serum lipid levels were analyzed. Using gene microarray, various core pathways, together with levels of gene expression within hepatocytes, were analyzed. RT-PCR was used to confirm the identity of the differentially expressed genes. MDG-1 could prevent obesity in HFD-induced mice and improve abnormal serum lipids. Besides, MDG-1 could regulate hyperlipidemia symptoms, specifically, and decrease fasting blood glucose, improve glucose tolerance, and ameliorate insulin resistance. According to results from gene microarray, most of the identified pathways were involved in the digestion and absorption of fat, biosynthesis, and catabolism of fatty acids as well as the secretion and biological synthesis of bile acids. Furthermore, MDG-1 may act upon peroxisome proliferator-activated receptors (PPAR) α and γ, activating PPARα whilst inhibiting PPARγ, thus having a potent hypolipidemic effect.
Insights
MDG-1, a compound from Ophiopogon japonicus, combats hyperlipidemia by preventing obesity and improving blood lipid levels in mice. It also helps regulate blood glucose and insulin resistance.
Area of Science:
- Biochemistry
- Pharmacology
- Metabolic Disorders
Background:
- Hyperlipidemia is a widespread metabolic disorder detrimental to health.
- MDG-1, a β-d-fructan from Ophiopogon japonicus, shows potential in managing lipid levels and diabetes.
- The precise mechanism of MDG-1 in treating hyperlipidemia requires elucidation.
Purpose of the Study:
- To investigate the hypolipidemic effects and underlying mechanisms of MDG-1 in a mouse model.
- To evaluate MDG-1's impact on obesity, serum lipids, glucose metabolism, and insulin resistance.
Main Methods:
- Male C57BL/6 mice were fed a low-fat diet, high-fat diet (HFD), or HFD with MDG-1.
- Evaluated body weight, serum lipid profiles, and glucose-related parameters.
- Utilized gene microarray and RT-PCR to analyze gene expression and metabolic pathways in hepatocytes.
Main Results:
- MDG-1 administration prevented diet-induced obesity and improved abnormal serum lipid profiles in mice.
- MDG-1 treatment decreased fasting blood glucose, enhanced glucose tolerance, and ameliorated insulin resistance.
- Gene microarray analysis revealed MDG-1 influences pathways related to fat digestion/absorption, fatty acid metabolism, and bile acid synthesis.
- MDG-1 may exert its hypolipidemic effect by modulating peroxisome proliferator-activated receptors (PPAR) α and γ.
Conclusions:
- MDG-1 demonstrates significant potential in managing hyperlipidemia and related metabolic dysfunctions.
- MDG-1's mechanism involves regulating lipid and glucose metabolism, potentially via PPAR signaling pathways.
